CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Hyperpolarized Helium-3 +2 moredrug
Likely dose
Hyperpolarized Helium-3 333mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00846287
NCT00846287N/ACompleted

Assessment of Arformoterol for COPD Using Hyperpolarized 3He MRI

University of Massachusetts, Worcester·interventional·Posted Feb 18, 2009·Updated Nov 1, 2012

In Brief

A clinical study evaluating Hyperpolarized Helium-3, Placebo, and 1 other intervention for Chronic Obstructive Pulmonary Disease. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to determine efficacy of MR imaging with hyperpolarized helium-3 gas in COPD patients both before and after treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2009
Enrollment StartNov 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.4 years ago

Interventions

Hyperpolarized Helium-3drug

Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.

Placebodrug

Subject will inhale a placebo (nebulized saline) with no drug.

Aformoteroldrug

Subjects will receive the drug arformoterol prior to scanning